Hansoh Pharmaceutical (03692.HK) Announces NMPA Approval for Clinical Trials of Novel Drug HS-10522 Tablets

Hansoh Pharma (03692) announced that HS-10522 tablets, a Class 1 new drug independently developed by the group, have received two clinical trial approval notices issued by the National Medical Products Administration (NMPA) of China. The drug is intended to be used for conducting clinical trials for "treating uncontrolled hypertension" and "treating primary aldosteronism," respectively.